Management of the Post-Surgery Hospital Care in France According to the Type of Surgery: A French Claims Database Analysis

Author(s)

Petrica N1, Rosé M1, Finas R1, Quinet A2, Lobel E2, Vidal A2
1Alira Health, Paris, France, 2RDS SAS, Strasbourg, France

Presentation Documents

OBJECTIVES: French HTA has set the goal of achieving 70% of outpatient surgical procedures by 2022, but a slowdown has been observed in recent years due to the existence of barriers linked to the risk of postoperative complications which concerns 10 to 15% of patients.1,2 It hinders the deployment of Enhanced Recovery After Surgery (ERAS) protocols, which remain sparsely used in France.

Remote monitoring medical devices (RMMD) can remove these barriers by facilitating and securing the early discharge of patients at risk of post-surgical complications.

The objective of this study is to describe the characteristics of post-surgical hospital care in France by major diagnostic categories.

METHODS: This is a retrospective transversal study based on French national claims hospitals database (PMSI), covering all public and private care centers in France.

Patients ≥ 18 years old who had at least one hospitalization for surgery in one of the three major diagnostic categories (MDC) (respiratory (RS), digestive (DS), and endocrine, nutritional, and metabolic (ENM)) in 2019 were included in the study.

The length of hospitalization (LH) and hospitalization severity (HS) were described by MDC separately.

RESULTS: For the three MDC, we identified 172,243 hospitalizations (RS: 33,614 (20%), DS: 101,714 (59%), ENM: 36,915 (21%)) including 8%, 8% and 16% of hospitalizations with ERAS protocol, respectively.

The LH was shorter with ERAS vs non-ERAS, -3.5 days for RS, -4.1 days for DS and -1.2 days for ENM and severe HS was less present in ERAS hospitalizations independent of MDC (14.2% vs 25% for RS, 33.8% vs 49.4% for DS, 1.3% vs 2.6% ENM).

CONCLUSIONS: This study provided a national understanding of the post-surgical practices in particular the LH reduction linked to ERAS and associated patient’s severity.

The observed size effect is a relevant input for clinical investigation design to assess the clinical and economic benefits of RMMDs.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

SA64

Topic

Medical Technologies, Study Approaches

Topic Subcategory

Medical Devices

Disease

SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Medical Devices

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×